Sasha A S Kjeldsen, Lasse H Hansen, Nathalie Esser, Steve Mongovin, Marie Winther-Sørensen, Katrine D Galsgaard, Jenna E Hunt, Hannelouise Kissow, Frederik R Ceutz, Dijana Terzic, Peter D Mark, Peter Plomgaard, Jens P Goetze, Gijs H Goossens, Ellen E Blaak, Carolyn F Deacon, Mette M Rosenkilde, Sakeneh Zraika, Jens J Holst, Nicolai J Wewer Albrechtsen
Context: Inhibitors of the protease neprilysin (NEP) are used for treating heart failure, but are also linked to improvements in metabolism. NEP may cleave proglucagon-derived peptides, including the glucose and amino acid (AA)-regulating hormone glucagon. Studies investigating NEP inhibition on glucagon metabolism are warranted. Objective: This work aims to investigate whether NEP inhibition increases glucagon levels. Methods: Plasma concentrations of glucagon and AAs were measured in eight healthy men during a mixed meal with and without a single dose of the NEP inhibitor/angiotensin II type 1 receptor antagonist, sacubitril/valsartan (194 mg/206 mg)...
September 1, 2021: Journal of the Endocrine Society